SUNPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | SUNPHARMA | Market Cap | 4,42,365 Cr. | Current Price | 1,843 ₹ | High / Low | 1,917 ₹ |
| Stock P/E | 147 | Book Value | 93.2 ₹ | Dividend Yield | 0.87 % | ROCE | 14.8 % |
| ROE | 12.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,792 ₹ | DMA 200 | 1,736 ₹ |
| Chg in FII Hold | -0.18 % | Chg in DII Hold | 0.28 % | PAT Qtr | 609 Cr. | PAT Prev Qtr | 872 Cr. |
| RSI | 54.7 | MACD | 27.3 | Volume | 15,14,266 | Avg Vol 1Wk | 25,08,177 |
| Low price | 1,547 ₹ | High price | 1,917 ₹ | PEG Ratio | -40.3 | Debt to equity | 0.61 |
| 52w Index | 80.1 % | Qtr Profit Var | -70.2 % | EPS | 10.9 ₹ | Industry PE | 31.6 |
📊 SUNPHARMA shows moderate momentum for intraday trading today. RSI at 54.7 indicates neutral strength, while MACD is positive (27.3), suggesting mild bullish sentiment. Current price (1,843 ₹) is above both 50 DMA (1,792 ₹) and 200 DMA (1,736 ₹), reflecting technical support. However, volume (15.1 lakh) is significantly lower than the weekly average, reducing conviction in price action.
- 💰 Optimal Buy Price: Around 1,835 ₹ – 1,845 ₹ (near support zone)
- 📈 Profit-Taking Levels: 1,870 ₹ – 1,890 ₹
- 📉 Stop-Loss Protection: 1,810 ₹
⏳ If already holding SUNPHARMA today, consider exiting intraday positions if price fails to sustain above 1,850 ₹ with improving volume. A break below 1,810 ₹ should trigger an exit to protect capital.
Positive ✅
- Strong market cap of 4,42,365 Cr. ensures liquidity
- Stock trading above both 50 DMA and 200 DMA
- ROCE at 14.8% and ROE at 12.8% show decent efficiency
- DII holding increased by 0.28%
Limitation ⚠️
- Extremely high P/E of 147 compared to industry average (31.6)
- EPS at 10.9 ₹ is modest relative to valuation
- Volume lower than weekly average, reducing momentum strength
- Dividend yield at 0.87% is low
Company Negative News ❌
- Quarterly PAT declined sharply from 872 Cr. to 609 Cr.
- Qtr Profit Var at -70.2% indicates significant earnings pressure
- FII holding reduced by 0.18%
Company Positive News 🌟
- Stock remains technically strong above key moving averages
- 52-week index at 80.1% shows investor confidence
Industry 🏭
- Industry PE at 31.6 vs SUNPHARMA PE at 147 – stock is highly overvalued
- Pharma sector remains defensive but sensitive to regulatory and R&D outcomes
Conclusion 📌
SUNPHARMA offers liquidity and technical support but faces valuation concerns and declining profitability. Intraday traders may attempt short-term gains near support levels with tight stop-losses. Caution is advised due to weak earnings trend and low volume participation.
Would you like me to extend this into a swing trade analysis with medium-term entry/exit zones and sector overlays?